{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '10.5.', 'Posting of information on publicly available registers and', 'publication policy', 'GSK assures that the key design elements of this protocol will be posted on the GSK', 'website and in publicly accessible database(s) such as clinicaltrials.gov, in compliance', 'with the current regulations.', 'GSK also assures that results of this study will be posted on the GSK website and in', 'publicly accessible regulatory registry(ies) within the required time-frame, in compliance', 'with the current regulations.', 'Studies that do not evaluate vaccines/products are progressed for publication in the', 'scientific literature when the results provide important scientific or medical knowledge or', 'are relevant for patient care, and will be considered for disclosure on the GSK website', 'and in publicly accessible regulatory registry(ies).', '10.6.', 'Provision of study results to investigators', 'Where required by applicable regulatory requirements, an investigator signatory will be', 'identified for the approval of the study report. The investigator will be provided', 'reasonable access to statistical tables, figures, and relevant reports and will have the', 'opportunity to review the complete study results at a GSK Biologicals site or other', 'mutually-agreed location.', 'GSK Biologicals will also provide the investigator with the full summary of the study', 'results. The investigator is encouraged to share the summary results with the study', 'subjects, as appropriate.', '10.7.', 'Data Sharing', 'Under the framework of the SHARE initiative, results of GSK studies may be combined', 'with non- GSK studies, to investigate further about the study product(s) and other', 'product(s), and /or the disease/condition under investigation and related diseases and', 'conditions.', '11.', 'COUNTRY SPECIFIC REQUIREMENTS', 'Not applicable.', '19-OCT-2018', '74', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '12.', 'REFERENCES', 'Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of', 'chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106: 196-204.', 'Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials:', 'from lung function to biomarkers. Eur Respir J. 2008; 31: 416-69.', 'Charlson ES, Bittinger K, Haas AR et al. Topographical continuity of bacterial', 'populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;', '184: 957-63.', 'Curran T, Coyle PV, McManus TE et al. Evaluation of real-time PCR for the detection', 'and quantification of bacteria in chronic obstructive pulmonary disease. FEMS Immunol', 'Med Microbiol. 2007; 50: 112-8.', 'De Serres G, Lampron N, La Forge J et al. Importance of viral and bacterial infections in', 'chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009; 46: 129-33.', 'Domenech A, Puig C, Mart\u00ed S et al. Infectious etiology of acute exacerbations in severe', 'COPD patients. J Infect. 2013; 67: 516-23.', 'Erb-Downward JR, Thompson DL, Han MK et al. Analysis of the lung microbiome in', 'the \"healthy\" smoker and in COPD. PLoS One. 2011; 6: e16384.', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the', 'diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease,', 'updated 2013. Available from:', 'http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf', 'Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the', 'diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease,', 'updated 2017. Available from:', 'p://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/', 'Guoping Hu, MD, PhD; Yumin Zhou, MD et al. Risk of COPD from Exposure to', 'Biomass Smoke: A Metaanalysis. CHEST. 2010; 138(1):20-31', 'Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic', 'obstructive pulmonary disease. N Engl J Med. 2004; 350: 2645-53.', 'Hui DS, Ip M, Ling T et al. A multicentre surveillance study on the characteristics,', 'bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute', 'exacerbations of chronic bronchitis. Respirology. 2011; 16: 532-9.', 'Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive', 'pulmonary disease. N Engl J Med. 2010; 363: 1128-38.', '19-OCT-2018', '75', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}